In contrast, the present study revealed a loss of ATF4 in clinical osteosarcoma samples and established BTZ-resistant osteosarcoma sublines, which suggests that osteosarcoma cells attain drug resistance by orchestrating adaptive signalling to prevent ATF4 upregulation. The gene discussed is ATF4; the disease is osteosarcoma.